New and updated clinical data presented by biopharma firms at the American Association for Cancer Research annual meeting, including: 23andme, Affimed, Astrazeneca, Genentech, Harbour Biomed, Humanigen, Immune-Onc, Innovent, Mina, Morphosys, Pieris, Quanta, Renovorx, Tempest.